Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 39 entries
Sorted by: Best Match Show Resources per page
Depression and heart disease: evidence of a link, and its therapeutic implications.

CNS drugs

Jiang W, Krishnan RR, O'Connor CM.
PMID: 11825102
CNS Drugs. 2002;16(2):111-27. doi: 10.2165/00023210-200216020-00004.

Over several decades, a large body of evidence has emerged to suggest that depressive disorder is a risk factor for heart diseases, both aetiologically and prognostically. Several large, prospective, longitudinal studies have examined the relationship between depression and the...

Cite
Jiang W, Krishnan RR, O'Connor CM. Depression and heart disease: evidence of a link, and its therapeutic implications. CNS Drugs. 2002;16(2):111-27doi: 10.2165/00023210-200216020-00004.
Jiang, W., Krishnan, R. R., & O'Connor, C. M. (2002). Depression and heart disease: evidence of a link, and its therapeutic implications. CNS drugs, 16(2), 111-27. https://doi.org/10.2165/00023210-200216020-00004
Jiang, Wei, et al. "Depression and heart disease: evidence of a link, and its therapeutic implications." CNS drugs vol. 16,2 (2002): 111-27. doi: https://doi.org/10.2165/00023210-200216020-00004
Jiang W, Krishnan RR, O'Connor CM. Depression and heart disease: evidence of a link, and its therapeutic implications. CNS Drugs. 2002;16(2):111-27. doi: 10.2165/00023210-200216020-00004. PMID: 11825102.
Copy Download .nbib Format: NLM
Overview of the field.

Metabolism: clinical and experimental

e Silva JA.
PMID: 15877305
Metabolism. 2005 May;54(5):5-9. doi: 10.1016/j.metabol.2005.01.005.

Clinical descriptions of depression date back to antiquity. Scientific investigations of mood disorders started only 150 years ago. An historical overview of depression leads into today's knowledge that depressive disorders are common, serious, and sometimes life-threatening and that their...

Cite
e Silva JA. Overview of the field. Metabolism. 2005;54(5):5-9doi: 10.1016/j.metabol.2005.01.005.
e Silva, J. A. (2005). Overview of the field. Metabolism: clinical and experimental, 54(5), 5-9. https://doi.org/10.1016/j.metabol.2005.01.005
e Silva, Jorge Alberto Costa. "Overview of the field." Metabolism: clinical and experimental vol. 54,5 (2005): 5-9. doi: https://doi.org/10.1016/j.metabol.2005.01.005
e Silva JA. Overview of the field. Metabolism. 2005 May;54(5):5-9. doi: 10.1016/j.metabol.2005.01.005. PMID: 15877305.
Copy Download .nbib Format: NLM
[Evaluation of depressive symptoms and resilience in patients on pharmacotherapeutic follow-up].

Revista de calidad asistencial : organo de la Sociedad Espanola de Calidad Asistencial

Gomes NC, Abrão PHO, Fernandes MR, Beijo LA, Marques LAM.
PMID: 28283261
Rev Calid Asist. 2017 Jul - Aug;32(4):215-220. doi: 10.1016/j.cali.2016.12.004. Epub 2017 Mar 07.

This study aimed to carry out the pharmacotherapeutic follow-up of patients with depression and to assess its impact on the resilience of the patients. Patients were followed-up for 8 months. The pharmacist evaluated depressive symptoms, resilience, and the need...

Cite
Gomes NC, Abrão PHO, Fernandes MR, et al. Evaluación de síntomas depresivos y resiliencia en pacientes bajo seguimiento farmacoterapéutico. [Evaluation of depressive symptoms and resilience in patients on pharmacotherapeutic follow-up]. Rev Calid Asist. 2017;32(4):215-220doi: 10.1016/j.cali.2016.12.004.
Gomes, N. C., Abrão, P. H. O., Fernandes, M. R., Beijo, L. A., & Marques, L. A. M. (2017). Evaluación de síntomas depresivos y resiliencia en pacientes bajo seguimiento farmacoterapéutico. [Evaluation of depressive symptoms and resilience in patients on pharmacotherapeutic follow-up]. Revista de calidad asistencial : organo de la Sociedad Espanola de Calidad Asistencial, 32(4), 215-220. https://doi.org/10.1016/j.cali.2016.12.004
Gomes, N C, et al. "Evaluación de síntomas depresivos y resiliencia en pacientes bajo seguimiento farmacoterapéutico." [Evaluation of depressive symptoms and resilience in patients on pharmacotherapeutic follow-up]. Revista de calidad asistencial : organo de la Sociedad Espanola de Calidad Asistencial vol. 32,4 (2017): 215-220. doi: https://doi.org/10.1016/j.cali.2016.12.004
Gomes NC, Abrão PHO, Fernandes MR, Beijo LA, Marques LAM. Evaluación de síntomas depresivos y resiliencia en pacientes bajo seguimiento farmacoterapéutico. [Evaluation of depressive symptoms and resilience in patients on pharmacotherapeutic follow-up]. Rev Calid Asist. 2017 Jul - Aug;32(4):215-220. doi: 10.1016/j.cali.2016.12.004. Epub 2017 Mar 07. Spanish. PMID: 28283261.
Copy Download .nbib Format: NLM
Using Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors in Critical Care: A Systematic Review of the Evidence for Benefit or Harm.

Critical care medicine

Kelly JM, Rubenfeld GD, Masson N, Min A, Adhikari NKJ.
PMID: 28338497
Crit Care Med. 2017 Jun;45(6):e607-e616. doi: 10.1097/CCM.0000000000002308.

OBJECTIVE: Selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitors are among the most commonly prescribed drugs in patients admitted to the ICU. Our objective was to systematically review available literature for evidence of benefit or harm in ICU patients resulting from...

Cite
Kelly JM, Rubenfeld GD, Masson N, et al. Using Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors in Critical Care: A Systematic Review of the Evidence for Benefit or Harm. Crit Care Med. 2017;45(6):e607-e616doi: 10.1097/CCM.0000000000002308.
Kelly, J. M., Rubenfeld, G. D., Masson, N., Min, A., & Adhikari, N. K. J. (2017). Using Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors in Critical Care: A Systematic Review of the Evidence for Benefit or Harm. Critical care medicine, 45(6), e607-e616. https://doi.org/10.1097/CCM.0000000000002308
Kelly, John M, et al. "Using Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors in Critical Care: A Systematic Review of the Evidence for Benefit or Harm." Critical care medicine vol. 45,6 (2017): e607-e616. doi: https://doi.org/10.1097/CCM.0000000000002308
Kelly JM, Rubenfeld GD, Masson N, Min A, Adhikari NKJ. Using Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors in Critical Care: A Systematic Review of the Evidence for Benefit or Harm. Crit Care Med. 2017 Jun;45(6):e607-e616. doi: 10.1097/CCM.0000000000002308. PMID: 28338497.
Copy Download .nbib Format: NLM
MicroRNAs in depression and suicide: Recent insights and future perspectives.

Journal of affective disorders

Dwivedi Y.
PMID: 30071418
J Affect Disord. 2018 Nov;240:146-154. doi: 10.1016/j.jad.2018.07.075. Epub 2018 Jul 24.

Suicide is a major public health concern. A significant proportion of depressed individuals show suicidal ideation. The currently available medications are not optimal and a large number of depressed/suicidal patients do not respond to these medications. Thus, there is...

Cite
Dwivedi Y. MicroRNAs in depression and suicide: Recent insights and future perspectives. J Affect Disord. 2018;240:146-154doi: 10.1016/j.jad.2018.07.075.
Dwivedi, Y. (2018). MicroRNAs in depression and suicide: Recent insights and future perspectives. Journal of affective disorders, 240146-154. https://doi.org/10.1016/j.jad.2018.07.075
Dwivedi, Yogesh. "MicroRNAs in depression and suicide: Recent insights and future perspectives." Journal of affective disorders vol. 240 (2018): 146-154. doi: https://doi.org/10.1016/j.jad.2018.07.075
Dwivedi Y. MicroRNAs in depression and suicide: Recent insights and future perspectives. J Affect Disord. 2018 Nov;240:146-154. doi: 10.1016/j.jad.2018.07.075. Epub 2018 Jul 24. PMID: 30071418; PMCID: PMC6108934.
Copy Download .nbib Format: NLM
Medicinal Marijuana, Stress, Anxiety, and Depression: .

Missouri medicine

Gold M.
PMID: 33311739
Mo Med. 2020 Sep-Oct;117(5):406-411.

No abstract available.

Cite
Gold M. Medicinal Marijuana, Stress, Anxiety, and Depression: . Mo Med. 2020;117(5):406-411
Gold, M. (2020). Medicinal Marijuana, Stress, Anxiety, and Depression: . Missouri medicine, 117(5), 406-411.
Gold, Mark. "Medicinal Marijuana, Stress, Anxiety, and Depression: ." Missouri medicine vol. 117,5 (2020): 406-411.
Gold M. Medicinal Marijuana, Stress, Anxiety, and Depression: . Mo Med. 2020 Sep-Oct;117(5):406-411. PMID: 33311739; PMCID: PMC7723145.
Copy Download .nbib Format: NLM
[Prevention of cyclothymia using lithium].

Deutsche medizinische Wochenschrift (1946)

Tölle R.
PMID: 5101289
Dtsch Med Wochenschr. 1971 Jan 08;96(2):77-8. doi: 10.1055/s-0028-1108206.

No abstract available.

Cite
Tölle R. Lithiumprophylaxe der Zyklothymie. [Prevention of cyclothymia using lithium]. Dtsch Med Wochenschr. 1971;96(2):77-8doi: 10.1055/s-0028-1108206.
Tölle, R. (1971). Lithiumprophylaxe der Zyklothymie. [Prevention of cyclothymia using lithium]. Deutsche medizinische Wochenschrift (1946), 96(2), 77-8. https://doi.org/10.1055/s-0028-1108206
Tölle, R. "Lithiumprophylaxe der Zyklothymie." [Prevention of cyclothymia using lithium]. Deutsche medizinische Wochenschrift (1946) vol. 96,2 (1971): 77-8. doi: https://doi.org/10.1055/s-0028-1108206
Tölle R. Lithiumprophylaxe der Zyklothymie. [Prevention of cyclothymia using lithium]. Dtsch Med Wochenschr. 1971 Jan 08;96(2):77-8. doi: 10.1055/s-0028-1108206. German. PMID: 5101289.
Copy Download .nbib Format: NLM
[Identification of the diagnostic symptoms of depression in relation to the response to medication].

Archivos de farmacologia y toxicologia

Roméu Bes J, Peris Arso A, Cuadras Avellana CM.
PMID: 546347
Arch Farmacol Toxicol. 1979 Dec;5(3):241-2.

No abstract available.

Cite
Roméu Bes J, Peris Arso A, Cuadras Avellana CM. Identificación de los síntomas-guía de la depresión en relación a la respuesta a la medicación. [Identification of the diagnostic symptoms of depression in relation to the response to medication]. Arch Farmacol Toxicol. 1979;5(3):241-2
Roméu Bes, J., Peris Arso, A., & Cuadras Avellana, C. M. (1979). Identificación de los síntomas-guía de la depresión en relación a la respuesta a la medicación. [Identification of the diagnostic symptoms of depression in relation to the response to medication]. Archivos de farmacologia y toxicologia, 5(3), 241-2.
Roméu Bes, J, et al. "Identificación de los síntomas-guía de la depresión en relación a la respuesta a la medicación." [Identification of the diagnostic symptoms of depression in relation to the response to medication]. Archivos de farmacologia y toxicologia vol. 5,3 (1979): 241-2.
Roméu Bes J, Peris Arso A, Cuadras Avellana CM. Identificación de los síntomas-guía de la depresión en relación a la respuesta a la medicación. [Identification of the diagnostic symptoms of depression in relation to the response to medication]. Arch Farmacol Toxicol. 1979 Dec;5(3):241-2. Spanish. PMID: 546347.
Copy Download .nbib Format: NLM
Relational barriers to depression help-seeking in primary care.

Patient education and counseling

Kravitz RL, Paterniti DA, Epstein RM, Rochlen AB, Bell RA, Cipri C, Fernandez y Garcia E, Feldman MD, Duberstein P.
PMID: 20570462
Patient Educ Couns. 2011 Feb;82(2):207-13. doi: 10.1016/j.pec.2010.05.007. Epub 2010 Jun 08.

OBJECTIVE: To identify attitudinal and interpersonal barriers to depression care-seeking and disclosure in primary care and in so doing, evaluate the primary care paradigm for depression care in the United States.METHODS: Fifteen qualitative focus group interviews in three cities....

Cite
Kravitz RL, Paterniti DA, Epstein RM, et al. Relational barriers to depression help-seeking in primary care. Patient Educ Couns. 2010;82(2):207-13doi: 10.1016/j.pec.2010.05.007.
Kravitz, R. L., Paterniti, D. A., Epstein, R. M., Rochlen, A. B., Bell, R. A., Cipri, C., Fernandez y Garcia, E., Feldman, M. D., & Duberstein, P. (2011). Relational barriers to depression help-seeking in primary care. Patient education and counseling, 82(2), 207-13. https://doi.org/10.1016/j.pec.2010.05.007
Kravitz, Richard L, et al. "Relational barriers to depression help-seeking in primary care." Patient education and counseling vol. 82,2 (2011): 207-13. doi: https://doi.org/10.1016/j.pec.2010.05.007
Kravitz RL, Paterniti DA, Epstein RM, Rochlen AB, Bell RA, Cipri C, Fernandez y Garcia E, Feldman MD, Duberstein P. Relational barriers to depression help-seeking in primary care. Patient Educ Couns. 2011 Feb;82(2):207-13. doi: 10.1016/j.pec.2010.05.007. Epub 2010 Jun 08. PMID: 20570462; PMCID: PMC2953600.
Copy Download .nbib Format: NLM
The right Rx for sadness.

U.S. news & world report

Kotz D.
PMID: 17853580
US News World Rep. 2007 Aug 06;143(4):58-61.

No abstract available.

Cite
Kotz D. The right Rx for sadness. US News World Rep. 2007;143(4):58-61
Kotz, D. (2007). The right Rx for sadness. U.S. news & world report, 143(4), 58-61.
Kotz, Deborah. "The right Rx for sadness." U.S. news & world report vol. 143,4 (2007): 58-61.
Kotz D. The right Rx for sadness. US News World Rep. 2007 Aug 06;143(4):58-61. PMID: 17853580.
Copy Download .nbib Format: NLM
Doing it for themselves.

Mental health today (Brighton, England)

Jackson C.
PMID: 17632816
Ment Health Today. 2007 Jun;10-1.

No abstract available.

Cite
Jackson C. Doing it for themselves. Ment Health Today. 2007;10-1
Jackson, C. (2007). Doing it for themselves. Mental health today (Brighton, England), 10-1.
Jackson, Catherine. "Doing it for themselves." Mental health today (Brighton, England) vol. (2007): 10-1.
Jackson C. Doing it for themselves. Ment Health Today. 2007 Jun;10-1. PMID: 17632816.
Copy Download .nbib Format: NLM
Parkinson's disease and depression.

Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology

Rihmer Z, Seregi K, Rihmer A.
PMID: 15787206
Neuropsychopharmacol Hung. 2004 Jun;6(2):82-5.

The prevalence of depression in Parkinson's disease is around 40%, but, unfortunately, such depression is frequently unrecognized and untreated. However, recognition and appropriate treatment of depression in patients with Parkinson's disease is essential for clinical practice. This review focuses...

Cite
Rihmer Z, Seregi K, Rihmer A. Parkinson's disease and depression. Neuropsychopharmacol Hung. 2004;6(2):82-5
Rihmer, Z., Seregi, K., & Rihmer, A. (2004). Parkinson's disease and depression. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 6(2), 82-5.
Rihmer, Zoltán, et al. "Parkinson's disease and depression." Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology vol. 6,2 (2004): 82-5.
Rihmer Z, Seregi K, Rihmer A. Parkinson's disease and depression. Neuropsychopharmacol Hung. 2004 Jun;6(2):82-5. PMID: 15787206.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 39 entries